Precision Longevity

The precision-longevity thesis is that whole-organism aging interventions have a ceiling because aging is not uniform across cell types. Rapamycin extends lifespan in some tissues but impairs others (e.g., spermatogenesis). Dietary restriction helps muscle and liver while stressing immune and reproductive tissues. The single-cell atlas era makes it possible, for the first time, to identify which cell types are the aging drivers in a given tissue and target them with precision delivery (LNPs, GalNAc, exosomes, viral vectors).

Chen, Wang, Gong, and Li at the Baylor Huffington Center on Aging frame the field's shift this way: conventional bulk-tissue analysis masks cell-type heterogeneity in aging. Single-cell atlases of C. elegans (~47,000 somatic cells), Drosophila (Aging Fly Cell Atlas), and mouse (PanSci, Tabula Muris Senis) reveal that individual cell populations age on different trajectories. The next step is integrating atlas data with targeted interventions.

This concept is the bridge between systemic longevity drugs (rapamycin, metformin, acarbose) and cell-specific cellular therapies (partial reprogramming, senolytics). It explains why the Life Biosciences trial targets a single eye rather than a systemic injection — and identifies the lack of human single-cell aging atlases as the key bottleneck holding back translation.

Key Claims

• Aging is not uniform — "Individual cell types in C. elegans age differently." Bulk analysis masks this. Evidence: strong (Precision Longevity)
• Systemic interventions have ceilings — rapamycin helps some tissues while impairing spermatogenesis; all whole-organism drugs have unavoidable tradeoffs. Evidence: strong (Precision Longevity)
• Cross-species conservation of core pathways — mTOR, insulin/IGF signaling, FOXO genes are conserved invertebrate-to-human, enabling translation. Evidence: strong (Precision Longevity)
• Atlas + delivery = precision — combining single-cell atlas findings with LNPs, GalNAc, exosomes, or viral vectors enables cell-type-specific interventions. Evidence: moderate (Precision Longevity)
• Human atlas gap — no comparable human aging atlases exist; this is the translation bottleneck. Evidence: strong (Precision Longevity)

Interventions Surveyed

• Genetic: insulin/IGF-1 suppression (daf-2/daf-16), mTOR inhibition, FOXO3 activation
• Lifestyle: dietary restriction, exercise + myokines, polyphenols
• Pharmacological: rapamycin/rapalogs, metformin, acarbose
• Cellular: senolytics (dasatinib, quercetin), partial reprogramming (see Partial Epigenetic Reprogramming), parabiosis/plasma exchange
• Delivery: LNPs, GalNAc, exosomes, viral vectors

Atlas Resources

Open Questions

• Which aging-vulnerable cell populations identified in model organisms are conserved in humans?
• Is adipose tissue a causal driver of systemic aging, or a downstream consequence?
• Aging shows nonlinear acceleration at ages 44 and 60 — what's optimal intervention timing?
• Can one intervention address multiple aging hallmarks in a single cell type without off-target damage?

Related Concepts

• Partial Epigenetic Reprogramming — reviewed as a cellular intervention
• Gene Therapy Delivery — LNPs/exosomes/viral vectors are the delivery substrate

Backlinks

Pages that reference this concept:

• Precision Longevity review
• Baylor Huffington Center on Aging

Changelog

• 2026-04-17 — Initial compilation from Baylor precision-longevity review.